The company behind the ubiquitous bubble wrap has won a consumer case against Visy Packaging, with the Federal Court awarding almost $3 million in damages after finding a spoon-lid combination supplied to yoghurt maker Chobani breached an exclusive licence agreement.
A data services company has failed to put the brakes on a patent infringement case by tech company Vehicle Monitoring Systems over a system used by the City of Melbourne for timing parked vehicles, despite arguing the case ended with a settlement five years ago.
BlueScope’s decision to hide its trade secrets has doomed its patent infringement lawsuit against South Korean rival Dongkuk Steel, with a judge dismissing the case and invalidating two of the steel giant’s patents.
A partner at Corrs Chambers Westgarth who successfully opposed a genome editing patent by ToolGen, and a corporate predecessor of law firm Ashurst, have been ordered to pay $375,000 in security in an appeal launched by the South Korean biotech firm.
Rio Tinto subsidiary Technological Resources has successfully challenged a decision by IP Australia to reject a patent application for a method of separating mined material, with a judge finding the claimed invention was not a collection of mere working directions as a delegate had found.
US investment manager State Street Global Advisors claims it lost out on royalties when Maurice Blackburn commissioned an allegedly infringing replica of its iconic Fearless Girl statue in New York City, a marketing phenomenon that has been estimated to be valued at up to $38.6 million.
Sherwood Chemicals wants to exterminate claims alleging it infringed two patents held by US chemical giant BASF for an underground termite control system, saying the patents were invalid and that any infringement, if it occurred, was innocent.
Israeli drug giant Teva and German drug maker Boehringer Ingelheim have settled their dispute over a patented capsule used to deliver the medicine in Boehringer’s top-selling inhaler Spiriva.
Veterinary pharmaceutical companies Norbrook Laboratories and Merial have launched twin appeals of two IP Australia decisions allowing Bayer to amend a proposed patent for a treatment for mammary gland infections.
A proposed Novartis patent for an oral form of its top-selling multiple sclerosis drug Gilenya is invalid for lack of inventive step, IP Australia has found, but gave the pharmaceutical giant a chance to amend.